Skip to content
Home/Companies/Biotech/TAAV

TAAV

Biotech·Spain·Exited 2020·Held 2yr
Entry
2018
Hold
2yr
Exit
2020

Who owns TAAV?

TAAV was owned by Columbus Venture Partners through Columbus Innvierte Life Science Fund I (2016 vintage) from 2018 to 2020, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-09

Columbus Venture Partners
Investor
Columbus Venture Partners
Columbus Innvierte Life Science Fund I · 2016 · Life Sciences VC

Key facts

HQSpain
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2020

More from Columbus Innvierte Life Science Fund I

Other portfolio companies in the same fund.

Artax Biopharma
Artax Biopharma
Active
BiotechUS· 2020
Aura Biosciences
Exited 2021
BiotechUS· 2018
Viralgen
Exited 2020
BiotechSpain· 2018
to
Algenex
Exited 2022
BiotechSpain· 2017
to
Curapath
Curapath
Exited 2021
PharmaSpain· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFrance· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track TAAV

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy TAAV?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on TAAV.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue